News headlines about Argos Therapeutics (NASDAQ:ARGS) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Argos Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.2168194632634 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Argos Therapeutics (ARGS) traded down $0.02 during trading on Friday, hitting $1.58. The stock had a trading volume of 397,244 shares, compared to its average volume of 895,540. The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29. The company has a market cap of $6.92, a price-to-earnings ratio of -0.07 and a beta of 0.99. Argos Therapeutics has a 12-month low of $1.53 and a 12-month high of $106.00.

Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.00) EPS for the quarter.

Separately, ValuEngine upgraded Argos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating and three have issued a hold rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $24.00.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Argos Therapeutics (ARGS) Share Price” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2018/02/09/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-argos-therapeutics-args-share-price.html.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Insider Buying and Selling by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.